CN Patent

CN119707808B — 一种制备cgrp受体拮抗剂中间体的方法

Assigned to Shanghai Synovar & Lab Co ltd · Expires 2025-12-05 · 0y expired

What this patent protects

本发明公开了一种制备CGRP受体拮抗中间体的方法，属于医药中间体合成领域。采用化合物1为原料，与盐酸羟胺在有机溶剂中反应生成中间体2，接着在还原剂存在下反应得到瑞美吉泮中间体3。本发明关键在于化合物1中R取代基采用大位阻硅基，确保还原反应时高度专一立体选择性。采用本发明方法得到的关键中间体，手性纯度高，操作简便，可实现后期该品种的产业化生产。

USPTO Abstract

本发明公开了一种制备CGRP受体拮抗中间体的方法，属于医药中间体合成领域。采用化合物1为原料，与盐酸羟胺在有机溶剂中反应生成中间体2，接着在还原剂存在下反应得到瑞美吉泮中间体3。本发明关键在于化合物1中R取代基采用大位阻硅基，确保还原反应时高度专一立体选择性。采用本发明方法得到的关键中间体，手性纯度高，操作简便，可实现后期该品种的产业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN119707808B
Jurisdiction
CN
Classification
—
Expires
2025-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Shanghai Synovar & Lab Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.